Overview

• CVS reported adjusted earnings of $1.81 per share on $98.9 billion in revenue for the second quarter, beating analyst forecasts of $1.46 and $94.5 billion
• The company raised its full-year 2025 adjusted EPS guidance to $6.30–$6.40 from $6.00–$6.20
• The pharmacy and consumer wellness segment generated $33.6 billion in sales, marking a 12.5% increase on higher prescription volumes despite ongoing reimbursement pressures
• Aetna’s medical loss ratio improved to 89.9% as tighter oversight and repricing measures reduced claims costs below Street estimates
• CVS reiterated plans to close 250 brick-and-mortar pharmacies this year and pursue about $2 billion in cost reductions as part of its turnaround strategy